UNSPSC 51281900: Antineoplastics

This classification denotes antibiotics that inhibit or prevent the proliferation of neoplasms, or proliferation of new abnormal growths of tissue, and which are therefore called ANTI-NEOPLASTICS, ANTINEOPLASTICS, or ANTINEOPLASTIC ANTIBIOTICS.

UNSPSC 51281900 Antineoplastics, a Class code, covers cancer medications and related pharmaceutical products that state and local health agencies, Medicaid programs, and public hospital systems procure for patient care and pharmacy benefit management. The scope of work under this code includes the sourcing, contracting, and supply chain management of chemotherapy agents, targeted cancer therapies, immunotherapies, and supportive care drugs used in oncology treatment, often through pharmacy benefit managers, group purchasing organizations, wholesalers, and increasingly through direct-to-manufacturer agreements that bypass traditional intermediaries. State health and human services agencies are the primary issuing bodies, particularly Medicaid programs and state employee health plans that manage prescription drug benefits at scale. These agencies issue RFIs, RFPs, and RFQs to establish pricing agreements, rebate structures, and fulfillment arrangements for antineoplastic medications as part of broader pharmacy benefit procurement strategies.

Recent activity centers on Texas, where the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities and market intelligence regarding direct-to-manufacturer prescription arrangements outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI seeks responses from vendors with experience in direct contracting for self-insured employers and government health plans, capacity to negotiate net pricing models without rebates, and ability to implement outcomes-based agreements. This preliminary information-gathering phase indicates state movement toward alternative supply chain structures for antineoplastics and other high-cost medications, with formal competitive solicitation and financial parameters likely to follow once vendor responses inform procurement strategy.